OMAHA, Neb., March 29, 2011 /PRNewswire/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO) today announced that it has discovered a novel sequencing technology, which the company has termed BLOCker-Sequencing (BLocking Oligonucleotides in Cycle sequencing), which enhances the limit of detection of standard Sanger Sequencing, enriches for direct sequencing of mutated DNA over wild-type (unmutated DNA) and can be run on standard Sanger Sequencing equipment.
BLOCker-Sequencing is an approach which selectively blocks the sequencing of wild-type DNA and allows samples with lower concentrations of mutant DNA to be sequenced for any mutation using standard Sanger Sequencing techniques. BLOCker-Sequencing can be easily used with any PCR amplified nucleic acid fragment with minimal modifications to the standard cycle sequencing protocols.
BLOCker-Sequencing incorporates two additional steps prior to annealing of the sequencing primer in the standard Sanger sequencing protocol, a hybridization of a blocking oligonucleotide which is complementary to the wild-type DNA sequence and then a denaturing step at a critical temperature at which the BLOCker-oligo remains annealed to the wild-type sequence but not the mutant sequence. The sequencing primer will then preferentially anneal and sequence the mutant but not the wild-type DNA.
Dr. Katherine Richardson, Transgenomic's Vice President of Research and Development, said, "Standard Sanger Sequencing is considered by many to be the gold standard in mutation detection and identification. However, it has limitations in finding low level DNA mutations such as those found in many cancers. If you have a tumor with a mutant to wild-type ratio of 1:10 or lower, you will most likely not detect the mutation using standard sequencing techniques. By adding BLOCker-Sequencing to the Sanger
|SOURCE Transgenomic, Inc.|
Copyright©2010 PR Newswire.
All rights reserved